Title:
PROPHYLACTIC OR THERAPEUTIC DRUG FOR NEURODEGENERATIVE DISEASES
Document Type and Number:
WIPO Patent Application WO/2020/145331
Kind Code:
A1
Abstract:
The purpose of the present invention is to provide a technique of administering rifampicin over an extended period of time, with reduced side effects. According to the present invention, a medicine that is for nasal administration and is used to prevent or treat neurodegenerative diseases, contains a rifampicin selected from the group consisting of rifampicin, derivatives thereof, and salts thereof, and a resveratrol selected from resveratrol and derivatives thereof, has reduced side effects, and can be administered over an extended period of time.
Inventors:
TOMIYAMA TAKAMI (JP)
UMEDA TOMOHIRO (JP)
KUMAGAI TORU (JP)
UMEDA TOMOHIRO (JP)
KUMAGAI TORU (JP)
Application Number:
PCT/JP2020/000392
Publication Date:
July 16, 2020
Filing Date:
January 09, 2020
Export Citation:
Assignee:
UNIV OSAKA PUBLIC CORP (JP)
MEDILABO RFP INC (JP)
MEDILABO RFP INC (JP)
International Classes:
A61K31/05; A23L33/10; A23L33/11; A61K31/496; A61P25/00; A61P25/28
Foreign References:
| US20110111014A1 | 2011-05-12 | |||
| JP2010524959A | 2010-07-22 | |||
| JP2013518034A | 2013-05-20 | |||
| JP2008527002A | 2008-07-24 |
Other References:
UEDA , TOMOHIRO ET AL.: "Nasal rifampicin - Prevention of dementia by a new administration route of rifampicin", DEMENTIA JAPAN, vol. 32, no. 3, 15 September 2018 (2018-09-15), pages 442, XP009522532, ISSN: 1342-646X
TAKAMI TOMIYAMA : "3. Search for the antidementia drug by drug repositioning", EXPERIMENTAL MEDICINE, vol. 35, no. 12, 30 November 2016 (2016-11-30), pages 233 - 239, XP009522536, ISSN: 0288-5514
NATÁLIA F NICOLETTI; VALNÊS RODRIGUES-JUNIOR; ANDRÉ A SANTOS; CARLOS E LEITE; ANA C O DIAS; ERALDO L BATISTA; LUIZ A BASSO; MARIA : "Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicin via SIRT1 modulation", JOURNAL OF NATURAL PRODUCTS, vol. 77, no. 10, 24 October 2014 (2014-10-24), pages 2190 - 2195, XP055724570, ISSN: 0163-3864, DOI: 10.1021/np5003143
IMÉNEZ-ARELLANES MARÍA ADELINA; GUTIÉRREZ-REBOLLEDO GABRIEL ALFONSO; MECKES-FISCHER MARIANA; LEÓN-DÍAZ ROSALBA: "Medical plant extracts and natural compounds with a hepatoprotective effect against damage caused by antitubercular drugs: A review", ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, vol. 9, no. 12, 9 November 2016 (2016-11-09), pages 1141 - 1149, XP029834637, ISSN: 1995-7645, DOI: 10.1016/j.apjtm.2016.10.010
TOMOHIRO UMEDA; AKIKO TANAKA; AYUMI SAKAI; AKIRA YAMAMOTO; TOSHIYASU SAKANE; TAKAMI TOMIYAMA: "Intranasal rifalllpicin for Alzheimer's disease prevention", ALZHEIMER'S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, vol. 4, no. 1, 1 January 2018 (2018-01-01), pages 304 - 313, XP055713181, ISSN: 2352-8737, DOI: 10.1016/j.trci.2018.06.012
TOMIYAMA, T.: "Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger", J BIOL CHEM, vol. 271, 1996, pages 6839 - 6844
YU W. ET AL.: "Cellular and molecular effects of resveratrol in health and disease", J CELL BIOCHEM, vol. 113, 2012, pages 752 - 759
TREDICI G ET AL.: "Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant?", DRUG EXP CLIN RES, vol. 25, 1999, pages 99 - 103
R. SCOTT TURNER ET AL.: "A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease", AMERICAN ACADEMY OF NEUROLOGY, 2015
BROWN VA. ET AL.: "Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis", CANCER RES, vol. 70, 2010, pages 9003 - 9011
EDWARDS JA ET AL.: "Safety of resveratrol with examples for high purity, trans-resveratrol, resVida((R", ANN N Y ACAD SCI, vol. 1215, 2011, pages 131 - 137
POPAT R ET AL.: "A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma", BR J HAEMATOL, vol. 160, 2013, pages 714 - 717, XP002769064, DOI: 10.1111/bjh.12154
TOMIYAMA ET AL., J NEUROSCI., vol. 30, 2010, pages 4845 - 56
UMEDA ET AL., BRAIN, vol. 139, 2016, pages 1568 - 86
LEE ET AL., PROC NATL ACAD SCI USA., vol. 99, 2002, pages 8968 - 73
MASUDA-SUZUKAKE ET AL., ACTA NEUROPATHOL COMMUN., vol. 2, 2014, pages 88
UMEDA T ET AL., AM. J. PATHOL., vol. 183, 2013, pages 211 - 225
YUICHI YAMASHITA ET AL.: "Induction of prolonged natural lifespans in mice exposed to acoustic environmental enrichment", SCIENTIFIC REPORTS, vol. 8, 2018
"WORLD HEALTH STATISTICS OVERVIEW 2019 MONITORING HEALTH FOR THE SDGs", WORLD HEALTH ORGANIZATION
See also references of EP 3909568A4
TAKAMI TOMIYAMA : "3. Search for the antidementia drug by drug repositioning", EXPERIMENTAL MEDICINE, vol. 35, no. 12, 30 November 2016 (2016-11-30), pages 233 - 239, XP009522536, ISSN: 0288-5514
NATÁLIA F NICOLETTI; VALNÊS RODRIGUES-JUNIOR; ANDRÉ A SANTOS; CARLOS E LEITE; ANA C O DIAS; ERALDO L BATISTA; LUIZ A BASSO; MARIA : "Protective effects of resveratrol on hepatotoxicity induced by isoniazid and rifampicin via SIRT1 modulation", JOURNAL OF NATURAL PRODUCTS, vol. 77, no. 10, 24 October 2014 (2014-10-24), pages 2190 - 2195, XP055724570, ISSN: 0163-3864, DOI: 10.1021/np5003143
IMÉNEZ-ARELLANES MARÍA ADELINA; GUTIÉRREZ-REBOLLEDO GABRIEL ALFONSO; MECKES-FISCHER MARIANA; LEÓN-DÍAZ ROSALBA: "Medical plant extracts and natural compounds with a hepatoprotective effect against damage caused by antitubercular drugs: A review", ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, vol. 9, no. 12, 9 November 2016 (2016-11-09), pages 1141 - 1149, XP029834637, ISSN: 1995-7645, DOI: 10.1016/j.apjtm.2016.10.010
TOMOHIRO UMEDA; AKIKO TANAKA; AYUMI SAKAI; AKIRA YAMAMOTO; TOSHIYASU SAKANE; TAKAMI TOMIYAMA: "Intranasal rifalllpicin for Alzheimer's disease prevention", ALZHEIMER'S & DEMENTIA: TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, vol. 4, no. 1, 1 January 2018 (2018-01-01), pages 304 - 313, XP055713181, ISSN: 2352-8737, DOI: 10.1016/j.trci.2018.06.012
TOMIYAMA, T.: "Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger", J BIOL CHEM, vol. 271, 1996, pages 6839 - 6844
YU W. ET AL.: "Cellular and molecular effects of resveratrol in health and disease", J CELL BIOCHEM, vol. 113, 2012, pages 752 - 759
TREDICI G ET AL.: "Resveratrol, map kinases and neuronal cells: might wine be a neuroprotectant?", DRUG EXP CLIN RES, vol. 25, 1999, pages 99 - 103
R. SCOTT TURNER ET AL.: "A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease", AMERICAN ACADEMY OF NEUROLOGY, 2015
BROWN VA. ET AL.: "Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis", CANCER RES, vol. 70, 2010, pages 9003 - 9011
EDWARDS JA ET AL.: "Safety of resveratrol with examples for high purity, trans-resveratrol, resVida((R", ANN N Y ACAD SCI, vol. 1215, 2011, pages 131 - 137
POPAT R ET AL.: "A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma", BR J HAEMATOL, vol. 160, 2013, pages 714 - 717, XP002769064, DOI: 10.1111/bjh.12154
TOMIYAMA ET AL., J NEUROSCI., vol. 30, 2010, pages 4845 - 56
UMEDA ET AL., BRAIN, vol. 139, 2016, pages 1568 - 86
LEE ET AL., PROC NATL ACAD SCI USA., vol. 99, 2002, pages 8968 - 73
MASUDA-SUZUKAKE ET AL., ACTA NEUROPATHOL COMMUN., vol. 2, 2014, pages 88
UMEDA T ET AL., AM. J. PATHOL., vol. 183, 2013, pages 211 - 225
YUICHI YAMASHITA ET AL.: "Induction of prolonged natural lifespans in mice exposed to acoustic environmental enrichment", SCIENTIFIC REPORTS, vol. 8, 2018
"WORLD HEALTH STATISTICS OVERVIEW 2019 MONITORING HEALTH FOR THE SDGs", WORLD HEALTH ORGANIZATION
See also references of EP 3909568A4
Attorney, Agent or Firm:
TANAKA, Junya et al. (JP)
Download PDF: